A double blind, placebo controlled, repeat dose study to compare the effectiveness of two doses of GSK256066 with placebo in reducing lung inflammation following segmental LPS [lipopolysaccharide] challenge in healthy volunteers.

Trial Profile

A double blind, placebo controlled, repeat dose study to compare the effectiveness of two doses of GSK256066 with placebo in reducing lung inflammation following segmental LPS [lipopolysaccharide] challenge in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs GSK 256066 (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease; Seasonal allergic rhinitis
  • Focus Biomarker; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Oct 2008 Status changed from recruiting to completed.
    • 22 Nov 2007 Status changed from initiated to recruiting.
    • 27 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top